Last Taboo for Hit Obesity Drug Is Asking When to Stop

US FDA Uncovers Fresh Faults at India’s Second-Biggest Drugmaker

Monster Close to Buying Rival Bang Energy For $362 Million

Ex-Pfizer Employee Charged With Illegal Trades on Paxlovid Trial

Dealmakers Adrift as $1 Trillion Vanishes in First-Half

Ipsen Gets FDA Advisers’ Backing for Rare Bone Disease Drug

Pfizer’s Exit Halves Japan Biotech Firm Value In Just Three Days

Irish GDP Growth to Stall as Pharma Exports Weaken, ESRI Says

Rise of Vocal Investors in Japan Is Fueling Hunt for IR Talent

Catalent Is Linked to Regeneron’s Eye-Drug Rejection in Latest Misstep

AstraZeneca to Fight Deforestation With 200 Million Trees: The London Rush

Asian Stocks Fluctuate Amid Recession Fears: Markets Wrap